Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: Evaluation of efficacy and safety based on kras mutation status (T-CORE0801)

Hiroshi Soeda, Hideki Shimodaira, Makio Gamoh, Hideaki Ando, Hideki Isobe, Takeshi Suto, Shin Takahashi, Yuichi Kakudo, Kenji Amagai, Takahiro Mori, Mika Watanabe, Takuhiro Yamaguchi, Shunsuke Kato, Chikashi Ishioka

Division of Cancer Science
Internal Medicine
Medicine
Special Clinical Facilities
MED - Public Health

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: Evaluation of efficacy and safety based on kras mutation status (T-CORE0801)'. Together they form a unique fingerprint.

Sort by
Weight
Alphabetically

Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: Evaluation of efficacy and safety based on kras mutation status (T-CORE0801)

Fingerprint

Biochemistry, Genetics and Molecular Biology

Pharmacology, Toxicology and Pharmaceutical Science